{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:16Z","timestamp":1783448296292,"version":"3.55.0"},"reference-count":88,"publisher":"Bioscientifica","issue":"11","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":237,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Alongside pulmonary and nutritional benefits, highly effective modulator therapies (HEMT) can promote an increase in body fat and raise the prevalence of overweight\/obesity, dyslipidemia, and hypertension in patients with cystic fibrosis. These metabolic changes will theoretically elevate cardiovascular risk in a population that has largely been unaffected by such complications until now. A rise in the prevalence of metabolic syndrome among HEMT-treated patients is expected, which has already prompted a review of dietary recommendations. Thus, a distinction must be made between patients with several years of care experience and those, especially younger patients or those with a late diagnosis of cystic fibrosis, who have not been educated on the principle of a high-calorie diet. Whether these metabolic changes will result in a greater incidence of cardiovascular events remains uncertain, underscoring the need to validate predictive risk scores in this context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0135","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:44:02Z","timestamp":1761043442000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Cardiometabolic insights in cystic fibrosis and highly effective modulator therapies: a narrative review"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9746-4489","authenticated-orcid":true,"given":"Fabian O","family":"Lurquin","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P","family":"Hermans","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gohy","sequence":"additional","affiliation":[{"name":"3"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Preumont","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2026070713502554300_bib1","volume-title":"2021 Annual Data Report","author":"Cystic Fibrosis Foundation Patient Registry","year":"2022"},{"key":"2026070713502554300_bib2","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026070713502554300_bib3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib5","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026070713502554300_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2026070713502554300_bib9","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026070713502554300_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1340388","article-title":"What the future holds: cystic fibrosis and aging","volume":"10","author":"Blankenship","year":"2024","journal-title":"Front Med"},{"key":"2026070713502554300_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026070713502554300_bib12","volume-title":"About the Division of Nutrition, Physical Activity, and Obesity","author":"National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)","year":"2025"},{"key":"2026070713502554300_bib13","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713502554300_bib14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026070713502554300_bib15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"2026070713502554300_bib16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0031-3955(16)33069-3","article-title":"Cystic fibrosis: a not-so-fatal disease","volume":"21","author":"Crozier","year":"1974","journal-title":"Pediatr Clin North Am"},{"key":"2026070713502554300_bib17","first-page":"760","volume-title":"Disorders of the Respiratory Tract in Children","author":"Shwachman","year":"1977"},{"key":"2026070713502554300_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"2026070713502554300_bib19","first-page":"246","article-title":"Consensus report on nutrition for pediatric patients with cystic fibrosis","volume":"35","author":"Borowitz","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026070713502554300_bib20","volume-title":"2023 Annual Data Report","author":"Cystic Fibrosis Foundation Patient Registry","year":"2024"},{"key":"2026070713502554300_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib22","volume-title":"ECFSPR 2022 Annual Report","author":"Zolin","year":"2024"},{"key":"2026070713502554300_bib23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib24","volume-title":"ECFS Patient Registry Annual Data Report","author":"Zolin","year":"2012"},{"key":"2026070713502554300_bib25","volume-title":"Australian Cystic Fibrosis Data Registry 2022 Annual Report. Report No 24.","author":"Monash University","year":"2023"},{"key":"2026070713502554300_bib26","volume-title":"2022 Annual Data Report: The Canadian Cystic Fibrosis Registry","author":"Cystic Fibrosis Canada","year":"2023"},{"key":"2026070713502554300_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib28","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation","volume":"42","author":"Knott-Torcal","year":"2023","journal-title":"Clin Nutr"},{"key":"2026070713502554300_bib29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"17","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026070713502554300_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: a follow-up study","volume":"123","author":"Navas-Moreno","year":"2024","journal-title":"Nutrition"},{"key":"2026070713502554300_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157459","article-title":"Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass","volume":"14","author":"Mouzaki","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026070713502554300_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026070713502554300_bib33","doi-asserted-by":"crossref","first-page":"e1248","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"Putman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib34","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib35","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westh\u00f6lter","year":"2024","journal-title":"Sci Rep"},{"key":"2026070713502554300_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1187735","article-title":"Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options","volume":"10","author":"Cesaro","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026070713502554300_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jcf.2019.01.002","article-title":"Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis","volume":"18","author":"Bellissimo","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.2005-2135","article-title":"Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis","volume":"91","author":"Moriconi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib39","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713502554300_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Ratti","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib42","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"key":"2026070713502554300_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111153","article-title":"Fatty acid abnormalities in cystic fibrosis\u2013the missing link for a cure?","volume":"27","author":"Drzyma\u0142a-Czy\u017c","year":"2024","journal-title":"iScience"},{"key":"2026070713502554300_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026070713502554300_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2026070713502554300_bib47","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/nu16193293","article-title":"Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"key":"2026070713502554300_bib48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","article-title":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","volume":"22","author":"Despotes","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib49","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"2026070713502554300_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib51","article-title":"One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026070713502554300_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"2026070713502554300_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcf.2012.03.006","article-title":"LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients","volume":"11","author":"Coderre","year":"2012","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2021.05.002","article-title":"Overweight and obesity in adults with cystic fibrosis: an Italian multicenter cohort study","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2012.08.012","article-title":"Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients","volume":"12","author":"Ishimo","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib56","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1515\/cclm-2015-1151","article-title":"Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: a preliminary study of plasma sterols","volume":"54","author":"Gelzo","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026070713502554300_bib57","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1515\/cclm-2019-1112","article-title":"Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis","volume":"58","author":"Gelzo","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2026070713502554300_bib58","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1111\/dom.15844","article-title":"Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance","volume":"26","author":"Bolduc","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026070713502554300_bib59","doi-asserted-by":"crossref","first-page":"e1670","DOI":"10.1210\/clinem\/dgae474","article-title":"A longitudinal study of glucose tolerance in cystic fibrosis: the central role of beta cell functional mass","volume":"110","author":"Piona","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib60","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis\u2013related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib62","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713502554300_bib63","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713502554300_bib64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"2026070713502554300_bib66","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713502554300_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of \u03b2-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","volume":"109","author":"Flatt","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2022.07.014","article-title":"Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes","volume":"22","author":"Potter","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib69","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"2026070713502554300_bib70","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: promise-endo","volume":"110","author":"Chan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713502554300_bib71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib73","doi-asserted-by":"crossref","first-page":"A3919","DOI":"10.1016\/j.chest.2023.07.2557","article-title":"Elexacaftor\/tezacaftor\/ivacaftor is associated with increased prevalence of hypertension in cystic fibrosis","volume":"164","author":"Ross","year":"2023","journal-title":"Chest"},{"key":"2026070713502554300_bib74","volume-title":"2020 Annual Data Report","author":"Cystic Fibrosis Foundation Patient Registry","year":"2021"},{"key":"2026070713502554300_bib75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s44161-022-00030-y","article-title":"Identifying and preventing cardiovascular disease in patients with cystic fibrosis","volume":"1","author":"Saunders","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2026070713502554300_bib76","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.3390\/jcm13195880","article-title":"A systematic review of metabolic syndrome: key correlated pathologies and non-invasive diagnostic approaches","volume":"13","author":"Giangregorio","year":"2024","journal-title":"J Clin Med"},{"key":"2026070713502554300_bib77","doi-asserted-by":"crossref","first-page":"2300174","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur Respir J"},{"key":"2026070713502554300_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00149-8","article-title":"WS07.04 impact of CFTR modulator therapy on cardiovascular risk in cystic fibrosis: a longitudinal cohort analysis","volume":"23","author":"England","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib79","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(23)00243-6","article-title":"WS10.03 increasing cardiovascular risk in adults with cystic fibrosis related diabetes receiving CFTR modulator therapy (elexacaftor\/tezacaftor\/ivacaftor)","volume":"22","author":"Chan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00491-0","article-title":"P133 presence of coronary calcium as a marker of coronary disease risk in adults with cystic fibrosis: a single centre study","volume":"23","author":"Gibson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"2026070713502554300_bib82","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070713502554300_bib83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713502554300_bib85","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070713502554300_bib86","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib87","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070713502554300_bib88","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/11\/EC-25-0135.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/11\/EC-25-0135.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0135\/504261\/ec-25-0135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0135\/504261\/ec-25-0135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:53:15Z","timestamp":1783446795000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/11\/e250135\/75319\/Cardiometabolic-insights-in-cystic-fibrosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":88,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0135","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"article-number":"e250135"}}